Labcorp Forecasts Steeper Fall In COVID-19 Testing Sales

  • Laboratory Corp of America Holdings LH posted Q3 revenues of $3.61 billion, a decrease of 11.2% Y/Y, missing the consensus of $3.79 billion.
  • The 10.7% decrease in organic revenue was driven by an 11.8% decrease in COVID-19 Testing, partially offset by a 1.1% increase in the company's organic Base Business.
  • "We continue to manage inflationary headwinds and labor constraints through our LaunchPad initiatives. And, we are accelerating the planned spin-off of our Clinical Development business to mid-2023 pending customary approvals," said Adam Schechter, chairman & CEO.
  • Adjusted operating margin compressed from 22.3% to 16.3%.
  • Diagnostic sales decreased 15.7% to $2.21 billion. Total volume (measured by requisitions) decreased by 10.3%.
  • The company posted an adjusted EPS of $4.68 versus $6.82 a year ago and a consensus of $4.67.
  • Guidance: Labcorp revised FY22 adjusted EPS guidance to $19.25-$20.25 compared to the prior range of $19.00-$21.25.
  • The company expects COVID-19 testing sales to decline (59.0%)-(57.0%) versus (60.0%)-(50.0%) expected earlier.
  • Price Action: LH shares are down 6.28% at $215.50 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefsHealth CareHealth Care Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!